The mission of the Case CCC Gene Expression &Genotyping Facility (GEGF) is to facilitate implementation of high throughput genetic technologies for the research conducted by members of the CWRU community. The GEGF serves as a technical and consulting resource for Cancer Center members, as well as other investigators laboratories at CWRU, UH, CCF, MHMC and the VAMC, in the areas of high throughput expression analysis and genotyping. It is the only facility of its capability in Cleveland. This Facility utilizes Affymetrix and Applied Biosystems (ABI) technologies as well as Next Generation Sequencing (NGS) to provide global and quantitative (on user-identified genes) gene expression analysis services. While the comprehensive and quantitative properties of NGS assays, for both RNA and DNA, now make these technologies an excellent choice for many genomic studies, these approaches are still very expensive and require extensive informatics expertise for generation of useful data. Therefore, the demand for microarray technology and real time PCR to identify global changes in gene expression and genetic variants in populations has remained at undiminished levels over the past several years. Microarrays have the distinct advantage of providing economical, rapid and readily accessible data that is generically comprehensive in scope, without an overwhelming requirement for computer capacity or informatics expertise. An important service provided by the GEGF, however, is provision of advice to individual investigators on the comparative limits and applicability of the broad range of available technologies for assessment of gene expression and genomic applications. Approximately 60 investigators use the GEGF every year and 30-50% of these are first time users, documenting that the GEGF continues to enjoy a healthy level of growth and a robust level of sustained work with repeat users. Since the last competitive renewal, the Core has provided services for 71 different Cancer Center Members, distributed in all 8 of the Scientific Programs. Part of the impact is through generation of preliminary data and grant support (letters of support;sections of grants;sections for manuscripts;slides for presentations), and the GEGF has played an important role in: determining in vivo targets of the 15-PGDH colon cancer tumor suppressor pathway;identifying CAN genes (Candidate Cancer Genes) in colon cancer;and determining a candidate list of genes involved in conferring resistance or sensitivity to hepatocellular carcinoma in mice fed a high fat diet.

Public Health Relevance

The Case Comprehensive Cancer Center is Northeast Ohio's only NCI designated comprehensive cancer center providing bench-to-bedside medical research involving partnerships between basic, clinical and population scientists to speed translation of laboratory discoveries into new prevention/intervention and cancer treatments.

National Institute of Health (NIH)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee B - Comprehensiveness (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Case Western Reserve University
United States
Zip Code
Zhao, S; Sedwick, D; Wang, Z (2015) Genetic alterations of protein tyrosine phosphatases in human cancers. Oncogene 34:3885-94
Dermawan, Josephine Kam Tai; Gurova, Katerina; Pink, John et al. (2014) Quinacrine overcomes resistance to erlotinib by inhibiting FACT, NF-?B, and cell-cycle progression in non-small cell lung cancer. Mol Cancer Ther 13:2203-14
Brubaker, Douglas; Difeo, Analisa; Chen, Yanwen et al. (2014) Drug Intervention Response Predictions with PARADIGM (DIRPP) identifies drug resistant cancer cell lines and pathway mechanisms of resistance. Pac Symp Biocomput :125-35
Yori, Jennifer L; Lozada, Kristen L; Seachrist, Darcie D et al. (2014) Combined SFK/mTOR inhibition prevents rapamycin-induced feedback activation of AKT and elicits efficient tumor regression. Cancer Res 74:4762-71
Dabir, Snehal; Kluge, Amy; McColl, Karen et al. (2014) PIAS3 activates the intrinsic apoptotic pathway in non-small cell lung cancer cells independent of p53 status. Int J Cancer 134:1045-54
Zapanta Rinonos, Serendipity; Rai, Urvashi; Vereb, Sydney et al. (2014) Sequential logic of polarity determination during the haploid-to-diploid transition in Saccharomyces cerevisiae. Eukaryot Cell 13:1393-402
Sizemore, Gina M; Sizemore, Steven T; Seachrist, Darcie D et al. (2014) GABA(A) receptor pi (GABRP) stimulates basal-like breast cancer cell migration through activation of extracellular-regulated kinase 1/2 (ERK1/2). J Biol Chem 289:24102-13
Sossey-Alaoui, Khalid; Pluskota, Elzbieta; Davuluri, Gangarao et al. (2014) Kindlin-3 enhances breast cancer progression and metastasis by activating Twist-mediated angiogenesis. FASEB J 28:2260-71
Dotan, Efrat; Devarajan, Karthik; D'Silva, A James et al. (2014) Patterns of use and tolerance of anti-epidermal growth factor receptor antibodies in older adults with metastatic colorectal cancer. Clin Colorectal Cancer 13:192-8
Arachiche, Amal; de la Fuente, MarĂ­a; Nieman, Marvin T (2014) Platelet specific promoters are insufficient to express protease activated receptor 1 (PAR1) transgene in mouse platelets. PLoS One 9:e97724

Showing the most recent 10 out of 975 publications